IQVIA (IQV)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-08
$203.90-2.08%
Close 2026-07-08 · 1-day change
Reading IQV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IQV free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-08
Reading IQV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IQV free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder, focusing on consistent growth in the healthcare sector. The current thesis state is intact, supported by strong recent financial performance and management's focus on growth.
The market appears to have priced in a neutral valuation, with IQV being seen as cheap compared to its peers. There is an expectations gap indicating that the market may not fully anticipate future growth potential.
Management has reaffirmed full-year revenue guidance, which suggests a commitment to growth. The R&D Solutions backlog is expanding, indicating future revenue streams, though there is some volatility in management execution.
The long-term thesis hinges on the performance of sector bellwethers like TMO, DHR, and IDXX. If these companies continue to perform well, it could provide a favorable backdrop for IQV. Conversely, any negative guidance from these peers could pose risks.
Overall, IQV's fundamentals are strong, but the investment thesis is sensitive to sector performance. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the view that the company's financial performance remains strong. However, there are concerns about potential slower growth impacting revenue guidance, which could challenge its core business narrative.
as of 2026-07-08
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: A slowdown in revenue growth could signal weakening demand or market challenges.
Confirms:Q2 revenue growth was less than 8% compared to last year.
Disproves:Q2 revenue growth was more than 8% compared to last year.
Why it matters: Growth in the R&D Solutions backlog shows future revenue potential. A strong backlog supports management's growth strategy.
Confirms:R&D Solutions backlog grows by over 7.9% each year.
Disproves:R&D Solutions backlog growth is less than 7.9% year-over-year.
Why it matters: Reaffirming revenue guidance shows confidence in future performance. It can boost investor trust.
Confirms:IQVIA confirms full-year 2026 revenue guidance of $17,150 million to $17,350 million in the next earnings call.
Disproves:IQVIA lowers or withdraws its 2026 revenue guidance.
Why it matters: Higher EPS guidance shows stronger earnings and more confidence from investors.
Confirms:The new Adjusted Diluted EPS guidance is now above $12.95.
Disproves:Adjusted Diluted EPS guidance stayed the same or dropped below $12.65.
Why it matters: Updates on share repurchases can show management's trust in the stock's value.
Confirms:Management will share news about more share buybacks next quarter.
Disproves:No updates on share repurchase activity will be given in the next quarter.
Why it matters: The revenue guidance shows management is confident in growth. This helps set investor hopes.
Confirms:Management says the revenue for 2026 will be between $15.325 billion and $15.575 billion.
Disproves:Management cuts the revenue guidance for 2026 to less than $15.325 billion.
Why it matters: Increased share repurchase can signal management's confidence in the company's value. It can also support share price.
Confirms:Actual share repurchases exceed $1 billion in Q2.
Disproves:Share repurchases are less than $1 billion in Q2.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.